The invention is directed to a particular class of metal complexes, specifically certain texaphyrin metal complexes, which both hydrolyze and photocleave RNA, and which also both hydrolyze RNA and photocleave DNA. In one embodiment, the present invention is directed to a method for both hydrolyzing and...http://www.google.com/patents/US5798491?utm_source=gb-gplus-sharePatent US5798491 - Multi-mechanistic chemical cleavage using certain metal complexes

The invention is directed to a particular class of metal complexes, specifically certain texaphyrin metal complexes, which both hydrolyze and photocleave RNA, and which also both hydrolyze RNA and photocleave DNA.

In one embodiment, the present invention is directed to a method for both hydrolyzing and photocleaving a polymer of ribonucleic acid, the method comprising the steps of contacting the polymer of ribonucleic acid with a texaphyrin metal complex exhibiting catalytic activity for both hydrolysis and photocleavage of ribonucleic acid polymers, incubating the polymer and the metal complex under conditions and for a time sufficient to hydrolyze the phosphate ester bond of the polymer, and exposing the texaphyrin metal complex to light for a time sufficient to photocleave the polymer.

In another embodiment of the present invention, the invention is directed to a method for both hydrolyzing a polymer of ribonucleic acid and photocleaving a polymer of deoxyribonucleic acid, the method comprising the steps of contacting a mixture of the ribonucleic acid polymer and the deoxyribonucleic acid polymer with a texaphyrin metal complex exhibiting catalytic activity for both hydrolysis of ribonucleic acid polymers and photocleavage of deoxyribonucleic acid polymers, incubating the polymer mixture and the metal complex under conditions and for a time sufficient to hydrolyze the phosphate ester bond of the ribonucleic acid polymer, and exposing the texaphyrin metal complex to light for a time sufficient to photocleave the deoxyribonucleic acid polymer.

Images(1)

Claims(27)

What is claimed is:

1. A method of both hydrolyzing and photocleaving a polymer of ribonucleic acid, the method comprising:

contacting the polymer of ribonucleic acid with a texaphyrin metal complex that exhibits catalytic activity for both hydrolysis and photocleavage of ribonucleic acid polymers,

incubating the polymer of ribonucleic acid and the metal complex under conditions and for a time sufficient to hydrolyze the phosphate ester bond of the polymer, and

exposing the texaphyrin metal complex to light for a time sufficient to photocleave the polymer.

2. The method of claim 1 wherein the texaphyrin metal complex is a texaphyrin-diamagnetic metal complex.

3. The method of claim 1 wherein the texaphyrin metal complex is a yttrium-texaphyrin complex.

4. The method of claim 1 wherein the light has a wavelength range of about 700-800 nm.

5. The method of claim 1 wherein the step of exposing the texaphyrin metal complex to light is carried out in the presence of oxygen.

6. The method of claim 1 wherein the texaphyrin metal complex has the formula: ##STR5## wherein, M is a divalent metal cation or a trivalent metal cation exhibiting catalytic activity for both hydrolysis and photocleavage of RNA polymers;

R6 and R9 are independently selected from the groups of R1 -R4, R7 and R8, with the proviso that the halide is other than iodide and the haloalkyl is other than iodoalkyl;

R5 and R10 -R12 are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, hydroxyalkyl, oxyalkyl, oxyhydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, carboxyalkyl, carboxyamide, carboxyamidealkyl, amino, aminoalkyl, or a couple to a saccharide, to a site-directing molecule or to a catalytic group; and

Z is an integer value less than or equal to 5.

7. The method of claim 6 wherein M is yttrium(III).

8. The method of claim 6 wherein at least one of R1 -R12 is a site-directing molecule, a catalytic group, a couple to a site-directing molecule or a couple to a catalytic group.

9. The method of claim 8 wherein the catalytic group is imidazole, guanidine, an amino acid, an amino acid derivative, a polyamino acid, an amine-substituted saccharide or a texaphyrin metal complex.

10. The method of claim 8 wherein the site-directing molecule is an oligonucleotide, a hormone, an antibody, a peptide having affinity for a biological receptor, or a sapphyrin molecule.

11. The method of claim 6 wherein at least one of R1 -R12 is a site-directing molecule, and the site-directing molecule is an oligonucleotide, which oligonucleotide has binding affinity for RNA.

12. The method of claim 11 wherein the oligonucleotide is a derivatized oligonucleotide or an oligonucleotide analog.

13. The method of claim 12 wherein the derivatized oligonucleotide is selected from the group consisting of methylphosphonates, phosphotriesters, phosphorothioates, and phosphoramidates.

14. The method of claim 12 wherein the derivatized oligonucleotide is 2'-O-alkyl oligoribonucleotide.

15. The method of claim 11 wherein the oligonucleotide is an antisense oligonucleotide.

16. A method of both hydrolyzing a polymer of ribonucleic acid and photocleaving a polymer of deoxyribonucleic acid, the method comprising:

contacting a mixture of the ribonucleic acid polymer and the deoxyribonucleic acid polymer with a texaphyrin metal complex that exhibits catalytic activity for both hydrolysis of ribonucleic acid polymers and photocleavage of deoxyribonucleic acid polymers,

incubating the polymer mixture and the metal complex under conditions and for a time sufficient to hydrolyze the phosphate ester bond of the ribonucleic acid polymer, and

exposing the texaphyrin metal complex to light for a time sufficient to photocleave the deoxyribonucleic acid polymer

wherein the metal is yttrium(III) or dysprosium(III).

17. The method of claim 16 wherein the light has a wavelength range of about 700-800 nm.

18. The method of claim 16 wherein the step of exposing the texaphyrin metal complex to light is carried out in the presence of oxygen.

19. The method of claim 16 wherein the texaphyrin metal complex has the formula: ##STR6## wherein, M is yttrium(III) or dysprosium(III);

R6 and R9 are independently selected from the groups of R1 -R4, R7 and R8, with the proviso that the halide is other than iodide and the haloalkyl is other than iodoalkyl;

R5 and R10 -R12 are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, hydroxyalkyl, oxyalkyl, oxyhydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, carboxyalkyl, carboxyamide, carboxyamidealkyl, amino, aminoalkyl, or a couple to a saccharide, to a site-directing molecule or to a catalytic group; and

Z is an integer value less than or equal to 5.

20. The method of claim 19 wherein M is yttrium(III).

21. The method of claim 19 wherein at least one of R1 -R12 is a site-directing molecule, a catalytic group, a couple to a site-directing molecule or a couple to a catalytic group.

22. The method of claim 21 wherein the catalytic group is imidazole, guanidine, an amino acid, an amino acid derivative, a polyamino acid, an amine-substituted saccharide or a texaphyrin metal complex.

23. The method of claim 21 wherein the site-directing molecule is an oligonucleotide, a hormone, an antibody, a peptide having affinity for a biological receptor, or a sapphyrin molecule.

24. The method of claim 23 wherein the oligonucleotide is a derivatized oligonucleotide or an oligonucleotide analog.

25. The method of claim 24 wherein the derivatized oligonucleotide is selected from the group consisting of methylphosphonates, phosphotriesters, phosphorothioates, and phosphoramidates.

26. The method of claim 24 wherein the derivatized oligonucleotide is 2'-O-alkyl oligoribonucleotide.

27. The method of claim 23 wherein the oligonucleotide is an antisense oligonucleotide.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part application of patent applications U.S. Ser. No. 08/452,261 filed May 26, 1995 now abandoned and U.S. Ser. No. 08/310,501 filed Sep. 21, 1994, now U.S. Pat. No. 5,567,687. U.S. Ser. No. 08/452,261 is a continuation of, and U.S. Ser. No. 08/310,501 is a continuation-in-part application of PCT/US94/06284 filed Jun. 9, 1994, which is a continuation-in-part application of U.S. Ser. No. 08/227,370 filed Apr. 14, 1994, now U.S. Pat. No. 5,559,207. U.S. Ser. No. 08/227,370 is a continuation-in-part application of U.S. Ser. No. 08/075,123 filed Jun. 9, 1993, now abandoned.

FIELD OF THE INVENTION

This invention relates to methods for both catalytically hydrolyzing polymers of ribonucleic acid and photocleaving polymers of ribonucleic acid and polymers of deoxyribonucleic acid with a single agent.

BACKGROUND OF THE INVENTION

The texaphyrins are aromatic pentadentate macrocyclic "expanded porphyrins" which have been found to be useful as MRI contrast agents, as radiosensitizers and in photodynamic therapy (PDT). They have also shown activity in phosphate ester and RNA hydrolysis or in RNA and DNA light-induced cleavage, depending on the metal with which they are complexed. Texaphyrin is considered as being an aromatic benzannulene containing both 18π- and 22π-electron delocalization pathways. See, e.g., Sessler, J. L. et al., Accounts of Chemical Research, 1994, 27:43. Texaphyrin molecules absorb strongly in the tissue-transparent 730-900 nm range, and they exhibit inherent selective uptake or biolocalization in certain tissues, particularly regions such as, for example, liver, atheroma or tumor tissue. Texaphyrins and water-soluble texaphyrins, method of preparation and various uses have been described in U.S. Pat. Nos. 4,935,498; 5,252,720; 5,256,399; 5,272,142; and 5,292,414; and, U.S. Ser. Nos. 08/135,118 and 08/196,964; all of which are incorporated herein by reference. Texaphyrins may be coupled to site-directing molecules to form conjugates for targeted in vivo delivery. Site-specific ester hydrolysis of RNA with a paramagnetic metal texaphyrin complex-oligonucleotide conjugate has been shown; see, Magda, D. et al., J. Am. Chem. Soc., 1994, 116:7439; and PCT publication WO 94/29316 (the entire disclosure of which is incorporated herein by reference). Site-specific light-induced photocleavage of DNA with a diamagnetic metal texaphyrin complex-oligonucleotide conjugate has also been carried out; see, Magda, D. et al., J. Am. Chem. Soc. 1995, 117:3629; and U.S. Ser. No. 08/310,501 (the entire disclosure of which is incorporated herein by reference).

While many texaphyrin metal complexes have been shown to promote the hydrolysis of phosphate ester bonds (see, WO 94/29316), and at the same time, other texaphyrin metal complexes have been shown to act as catalysts for the light-induced cleavage (photocleavage) of DNA and RNA (see, U.S. Ser. No. 08/310,501), it has not been previously shown that a single texaphyrin metal complex would both hydrolyze and photocleave RNA, or would both hydrolyze RNA and photocleave DNA. Such a texaphyrin complex would be very useful in practical terms, since only one metal complex would be necessary to perform a variety of functions. This is especially important in in vivo treatment situations where it is desirable for only a relatively small amount of material to be present. It is also desirable where the metal complex itself, such as for example where the complex is an oligonucleotide conjugate, is quite expensive or can be produced in only small quantities. Additionally, while two separate conjugates could be employed to cover both photocleavage and hydrolysis activities, respectively, the conjugates would compete with one another.

SUMMARY OF THE INVENTION

The inventors have now discovered a particular class of texaphyrin metal complexes which both hydrolyzes and photocleaves RNA. This class of complexes also both hydrolyzes RNA and photocleaves DNA.

In particular, in one embodiment, the present invention is directed to a method for both hydrolyzing and photocleaving a polymer of ribonucleic acid, the method comprising the steps of contacting the RNA polymer with a texaphyrin metal complex having catalytic activity for both hydrolysis and photocleavage of RNA polymers, incubating the RNA polymer and the metal complex under conditions and for a time sufficient to hydrolyze the phosphate ester bond of the polymer, and exposing the texaphyrin metal complex to light for a time sufficient to photocleave the RNA polymer.

In another embodiment of the present invention, the invention is directed to a method for both hydrolyzing a polymer of ribonucleic acid and photocleaving a polymer of deoxyribonucleic acid, the method comprising the steps of contacting a mixture of the ribonucleic acid polymer and the deoxyribonucleic acid polymer with a texaphyrin metal complex having catalytic activity for both hydrolysis of RNA polymers and photocleavage of DNA polymers, incubating the polymer mixture and the metal complex under conditions and for a time sufficient to hydrolyze the phosphate ester bond of the ribonucleic acid polymer, and exposing the texaphyrin metal complex to light for a time sufficient to photocleave the deoxyribonucleic acid polymer.

The present invention discloses the use of a single texaphyrin metal complex to perform two separate chemical reactions. Specifically, the texaphyrin metal complex exhibits the ability to catalyze both hydrolysis and photocleavage reactions. In one reaction, a phosphate ester bond is cleaved by hydrolysis; that is, the cleavage is a hydrolytic reaction where a water molecule is added across an ester bond to break the bond. This hydrolytic reaction is particularly useful for cleaving the phosphate ester bonds of a polymer of RNA, and is not dependent on the presence or absence of light. The second reaction, by comparison, is a photolytic cleavage reaction; that is, the texaphyrin metal complex, when irradiated in the presence of oxygen serves to produce cytotoxic materials, such as singlet oxygen, which products then cause strand damage or breakage, or "photocleavage", of a polymer of DNA or RNA. Not wanting to be bound by theory, it is possible that singlet oxygen attacks a purine base, such as guanine for example, and causes depurination of double-stranded DNA similar to the Maxam and Gilbert chemical cleavage of DNA. It is important to note that while strand breakage, as outlined herein, is useful for quantitating the extent of photochemically derived damage, this damage in itself (e.g., modification of a nucleotide) is known to inhibit biological function of the biopolymer (for example, translation of RNA, phage infectivity). This photocleavage reaction is dependent on the presence of light, and in particular light in the spectral range of about 700 to 800 nm, where living tissues are relatively transparent.

The ability of a single agent to catalyze both types of cleavage reactions is especially useful in the design of therapy treatments which take advantage of both hydrolysis and photocleavage mechanisms. Thus, for example, a single texaphyrin metal complex can be targeted to a particular RNA, such as an antisense texaphyrin complex-oligonucleotide conjugate directed to a target mRNA. This metal complex-conjugate is administered to a patient, after which light is applied in proximity to the metal complex and the target mRNA to cause photocleavage of the RNA. The texaphyrin complex is not destroyed during the photocleavage reaction, so that after the light is removed, the complex-conjugate remains to cleave, via light-independent hydrolysis, any target RNA which may remain. In a second example, a single texaphyrin metal complex can be used in the cleavage and destruction of two different targets, one RNA-based and the other DNA-based, via hydrolytic and photocleavage action. In contrast to using two agents, each targeting either RNA or DNA only, the use of one agent to target both RNA and DNA precludes the reduction in efficiency, caused by the presence of two competing agents. Additionally, less total drug needs to be utilized to effect the desired result.

The methods of the present invention are conducted under conditions sufficient to hydrolyze the RNA and photocleave the DNA or RNA. Such conditions are known to those of skill in the art or can be determined by such persons without undue experimentation. It has been found that such conditions include physiologic conditions. This is especially useful when the texaphyrin complexes are used in vivo as a treatment procedure to hydrolyze RNA and also photocleave RNA or DNA.

In the practice of the present invention, the texaphyrin macrocycle to be complexed to the metal ion may be chosen from any texaphyrin molecule, including those now known and disclosed in the U.S. patents and patent applications incorporated by reference herein. Representatives of texaphyrin metal complexes included within the present invention are encompassed within the following formula: ##STR1##

M is a divalent metal cation or a trivalent metal cation exhibiting catalytic activity for both hydrolysis of RNA polymers and photocleavage of RNA or DNA polymers. Metals useful in the present invention may include, but are not necessarily limited to, cadmium(II), yttrium(III), indium(III), lanthanum(III), lutietium(III), and other diamagnetic metal cations.

R6 and R9 are independently selected from the groups of R1 -R4, R7 and R8, with the proviso that the halide is other than iodide and the haloalkyl is other than iodoalkyl.

R5 and R10 -R12 are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, hydroxyalkyl, oxyalkyl, oxyhydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, carboxyalkyl, carboxyamide, carboxyamidealkyl, amino, aminoalkyl, or a couple to a saccharide, to a site-directing molecule or to a catalytic group.

The charge, Z, is an integer value less than or equal to 5. In the context of the basic macrocycle with a yttrium cation, Z is 1 or 2. However, one skilled in the art in light of the present disclosure would realize that the charge Z would be altered so as to account for the choice of metal M, the pH under consideration, and charges present on any of substituents R1 -R12 and charges present on any covalently bound site-directing molecule, for example charges of the phosphate groups on an oligonucleotide. For instance, if R1 =carboxyl and R2 -R12 =alkyl and the metal M=Lu+3, and the solution is pH=7 (so that R1 =CO2 --), the charge Z would be zero. The charge would be negative when substituents have a sufficient number of negative charges, for example, when a substituent is an oligonucleotide. The charge would be +5, for example, when the M is Lu+3 and the net charge of a substituent(s) is three positive charges.

"Alkyl" means alkyl groups, straight, branched or cyclic isomers, with generally one to fifty, preferably one to thirty, more preferably one to ten, carbon atoms.

"Alkenyl" means alkenyl groups, straight, branched or cyclic isomers, with generally two to fifty, preferably two to thirty, more preferably two to ten, carbon atoms, and with one to five or more double bonds, preferably one to five, more preferably one to three double bonds.

"Alkynyl" means alkenyl groups, straight, branched or cyclic isomers, with generally two to fifty, preferably two to thirty, more preferably two to ten, carbon atoms, and with one to five or more triple bonds, preferably one to five, more preferably one to three triple bonds.

"Hydroxyalkyl" means alcohols of alkyl groups. Preferred are hydroxyalkyl groups having one to twenty, more preferably one to ten, hydroxyls. "Hydroxyalkyl" is meant to include polyethers with one or more functional groups; diols of alkyls, with diols of C1-10 alkyls being preferred, and diols of C1-3 alkyls being more preferred; and polyethylene glycol, polypropylene glycol and polybutylene glycol as well as polyalkylene glycols containing combinations of ethylene, propylene and butylene.

"Oxyalkyl" means alkyl groups as herein described with oxygen atoms, including ether linkages. The number of repeating oxyalkyls within a substituent may be up to 200, preferably from 1 to 20, more preferably from 1 to 7, and most preferably is 2-3. A preferred oxyalkyl is O(CH2 CH2 O)x CH3 where x=1-100, preferably 1-10, and more preferably, 2-3.

"Hydroxyalkoxy" means alkyl groups as described herein having ether or ester linkages, as well as hydroxyl groups, substituted hydroxyl groups, carboxyl groups, substituted carboxyl groups or the like.

"Carboxy" groups include carboxylic acids of the alkyls described herein as well as aryl carboxylic acids such as benzoic acid. "Carboxyalkyl" means alkyl groups having hydroxyl groups, carboxyl or amide substituted ethers, ester linkages, tertiary amide linkages removed from the ether or the like. Representative examples of "carboxyamides" include primary carboxyamides (CONH2), and secondary (CONHR') and tertiary (CONR'R") carboxyamides where each of R' and R" is a functional group as described herein. "Carboxyamidealkyl" means alkyl groups with hydroxyl groups, secondary or tertiary amide linkages or the like.

Representatives of useful amines include a primary, secondary or tertiary amine of an alkyl as described hereinabove.

"Aryl" is an aromatic group, such as a benzyl or a phenyl group for example, unsubstituted or substituted with a nitro, carboxy, sulfonic acid, hydroxy, oxyalkyl, or halide.

The term "saccharide" includes oxidized, reduced or substituted saccharide; hexoses such as D-glucose, D-mannose or D-galactose; pentoses such as D-ribose or D-arabinose; ketoses such as D-ribulose or D-fructose; disaccharides such as sucrose, lactose, or maltose; derivatives such as acetals, amines, and phosphorylated sugars; oligosaccharides; as well as open chain forms of various sugars, and the like. Examples of amine-derivatized sugars are galactosamine, glucosamine, and sialic acid.

For the above texaphyrins, oxyhydroxyalkyl may be alkyl having independently hydroxy substituents and ether branches or may be C.sub.(n-x) H.sub.((2n+1)-2x) Ox Oy or OC.sub.(n-x) H.sub.((2n+1)-2x) Ox Oy where n is a positive integer from 1 to 10; x is zero or a positive integer less than or equal to n; and y is zero or a positive integer less than or equal to ((2n+1)-2x).

The oxyhydroxyalkyl or saccharide may be Cn H.sub.((2n+1)-q) Oy Raq, OCn H.sub.((2n+1)-q) Oy Raq or (CH2)n CO2 Ra where n is a positive integer from 1 to 10; y is zero or a positive integer less than or equal to ((2n+1)-q); q is zero or a positive integer less than or equal to (2n+1); and Ra is independently H, alkyl, hydroxyalkyl, saccharide, C.sub.(m-w) H.sub.((2m+1)-2w) Ow Oz, O2 CC.sub.(m-w) H.sub.((2m+1)-2w) Ow Oz or N(R)OCC.sub.(m-w) H.sub.((2m+1)-2w) Ow Oz, where m is a positive integer from 1 to 10, w is zero or a positive integer less than or equal to m, z is zero or a positive integer less than or equal to ((2m+1)-2w), and R is H, alkyl, hydroxyalkyl, or Cm H.sub.((2m+1)-r) Oz Rbr where m is a positive integer from 1 to 10, z is zero or a positive integer less than ((2m+1)-r), r is zero or a positive integer less than or equal to 2m+1, and Rb is H, alkyl, hydroxyalkyl, or saccharide.

The carboxyamidealkyl may be (CH2)n CONHRa, O(CH2)n CONHRa, (CH2)n CON(Ra)2, or O(CH2)n CON(Ra)2 where n is a positive integer from 1 to 10; Ra is independently H, alkyl, hydroxyalkyl, saccharide, C.sub.(m-w) H.sub.((2m+1)-2w) Ow Oz, O2 CC.sub.(m-w) H.sub.((2m+1)-2w) Ow Oz or N(R)OCC.sub.(m-w) H.sub.((2m+1)-2w) Ow Oz, where m is a positive integer from 1 to 10, w is zero or a positive integer less than or equal to m, z is zero or a positive integer less than or equal to ((2m+1)-2w), and R is H, alkyl, hydroxyalkyl, or Cm H.sub.((2m+1)-r) Oz Rbr where m is a positive integer from 1 to 10, z is zero or a positive integer less than ((2m+1)-r), r is zero or a positive integer less than or equal to 2m+1, and Rb is H, alkyl, hydroxyalkyl, or saccharide.

The carboxyalkyl may be Cn H.sub.((2n+1)-q) Oy Rcq or OCn H.sub.((2n+1)-q) Oy Rcq where n is a positive integer from 1 to 10; y is zero or a positive integer less than or equal to ((2n+1)-q); q is zero or a positive integer less than or equal to (2n+1); and Rc is (CH2)n CO2 Rd, (CH2)n CONHRd, or (CH2)n CON(Rd)2 where n is a positive integer from 1 to 10, and Rd is H, alkyl, hydroxyalkyl, saccharide, C.sub.(m-w) H.sub.((2m+1)-2w) Ow Oz, O2 CC.sub.(m-w) H.sub.((2m+1)-2w) Ow Oz or N(R)OCC.sub.(m-w) H.sub.((2m+1)-2w) Ow Oz, where m is a positive integer from 1 to 10, w is zero or a positive integer less than or equal to m, z is zero or a positive integer less than or equal to ((2m+1)-2w), and R is H, alkyl, hydroxyalkyl, or Cm H.sub.((2m+1)-r) Oz Rbr where m is a positive integer from 1 to 10, z is zero or a positive integer less than ((2m+1)-r), r is zero or a positive integer less than or equal to 2m+1, and Rb is H, alkyl, hydroxyalkyl, or saccharide.

Hydrolytic cleavage of phosphate ester bonds, and particularly of RNA, by texaphyrin complexes may be enhanced by additional catalytic groups appended to the texaphyrin complex or to a texaphyrin complex-site directing molecule conjugate. The term "catalytic group" means a chemical functional group that assists catalysis by acting as a general acid, Br.o slashed.nsted acid, general base, Br.o slashed.nsted base, nucleophile, or any other means by which the activation barrier to reaction is lowered or the ground state energy of the substrate is increased. Exemplary catalytic groups contemplated include, but are not limited to, imidazole; guanidine; substituted saccharides such as D-glucosamine, D-mannosamine, D-galactosamine, D-glucamine and the like; amino acids such as L-histidine and L-arginine; derivatives of amino acids such as histamine; polymers of amino acids such as poly-L-lysine, (LysAla)n, (LysLeuAla)n where n is from 1-30 or preferably 1-10 or more preferably 2-7 and the like; derivatives thereof; and texaphyrin metal complexes. The term "appended to the texaphyrin complex-site directing molecule conjugate" means that the catalytic groups are attached either directly to the texaphyrin metal complex or to the texaphyrin complex via a linker or couple of variable length, or are attached to the ligand portion of a texaphyrin complex-ligand conjugate either with or without a linker or couple of variable length.

Exemplary site-directing molecules useful herein include, but are not limited to, polydeoxyribonucleotides, oligodeoxyribonucleotides, polyribonucleotide analogs, oligoribonucleotide analogs, polyamides including peptides having affinity for a biological receptor and proteins such as antibodies, steroids and steroid derivatives, hormones such as estradiol or histamine, hormone mimics such as morphine, and further macrocycles such as sapphyrins and rubyrins.

The oligonucleotides may be derivatized at the bases, the sugars, the ends of the chains, or at the phosphate groups of the backbone to promote in vivo stability. Modifications of the phosphate groups are preferred in one embodiment since phosphate linkages are sensitive to nuclease activity. Presently preferred derivatives are the methylphosphonates, phosphotriesters, phosphorothioates, and phosphoramidates. Additionally, the phosphate linkages may be completely substituted with non-phosphate linkages such as amide linkages. Appendages to the ends of the oligonucleotide chains also provide exonuclease resistance. Sugar modifications may include groups, such as halo, alkyl, alkenyl or alkoxy groups, attached to an oxygen of a ribose moiety in a ribonucleotide. In a preferred embodiment, the group will be attached to the 2' oxygen of the ribose. In particular, halogen moieties such as fluoro may be used. The alkoxy group may be methoxy, ethoxy or propoxy. The alkenyl group is preferably allyl. The alkyl group is preferably a methyl group and the methyl group is attached to the 2' oxygen of the ribose. Other alkyl groups may be ethyl or propyl.

It is understood that the terms "nucleotide", "polynucleotide" and "oligonucleotide", as used herein and in the appended claims, refer to both naturally-occurring and synthetic nucleotides, poly- and oligonucleotides and to analogs and derivatives thereof such as methylphosphonates, phosphotriesters, phosphorothioates, phosphoramidates and the like. Deoxyribonucleotides, deoxyribonucleotide analogs and ribonucleotide analogs are contemplated as site-directing molecules in the present invention.

The term "texaphyrin-oligonucleotide conjugate" means that an oligonucleotide is attached to the texaphyrin in a 5' or a 3' linkage, or in both types of linkages to allow the texaphyrin to be an internal residue in the conjugate. It can also refer to a texaphyrin that is linked to an internal base of the oligonucleotide. The oligonucleotide or other site-directing molecule may be attached either directly to the texaphyrin or to the texaphyrin via a linker or a couple of variable length. During catalysis, for example, the texaphyrin portion of a texaphyrin metal complex-oligonucleotide conjugate is placed in the vicinity of the substrate upon binding of the oligonucelotide to the targeted nucleic acid substrate.

A conjugated group having site specificity or catalytic activity may be covalently coupled to a texaphyrin directly on the macrocycle ring or through various couples. A couple may be described as a linker, i.e., the covalent product formed by reaction of a reactive group designed to attach covalently another molecule at a distance from the texaphyrin macrocycle. Exemplary linkers or couples are amides, amine, disulfide, thioether, ether, ester, or phosphate covalent bonds. In preferred embodiments, conjugates and appended groups are covalently bonded to the texaphyrin via a carbon--carbon, a carbon--nitrogen, a carbon--sulfur, or a carbon--oxygen bond, more preferred being a carbon--oxygen or a carbon--nitrogen bond.

In the practice of the present invention, in a preferred embodiment at least one of R1 -R12 is a site-directing molecule or is a couple to a site-directing molecule. Also presently preferred are those compounds where R1 is hydroxyalkyl and R2, R3, and R4 are alkyl. R7 and R8 may be hydroxyalkoxy or oxyalkyl. Alternatively, R3, R7 or R8 may be a site-directing molecule or a couple to a site-directing molecule. Preferred site-directing molecules are a hormone or an oligonucleotide, more preferably an oligonucleotide. The oligonucleotide may be a deoxyribonucleotide, a deoxyribonucleotide derivative or analog, or a ribonucleotide analog. A presently preferred ribonucleotide analog, for example, has alkyl groups, more preferably methyl groups, on the 2' oxygen of the ribose. A presently preferred deoxyribonucleotide analog is a phosphorothioate or a phosphoramidate.

In a further preferred texaphyrin complex of the present invention, R1 is (CH2)2 CH2 OH, R2 and R3 are CH2 CH3, R4 is CH3, and R7 and R8 are OCH2 CH2 CH2 OH or R7 and R8 are O(CH2 CH2 O)t CH2 CH2 OR' where t is zero to 10, preferably zero to 3, and R' is H or CH3. Alternatively, R8 is a site-directing molecule or a couple thereto, preferably an oligonucleotide or a couple thereto, more preferably O(CH2)n CO-oligonucleotide where n is 1-7 and preferably 1-3. Where R8 is a site-directing molecule or a couple thereto, R7 may be H, OCH3 or one of the previously listed preferred substituents.

A presently preferred metal is yttrium(III).

Water-soluble texaphyrins are often preferred for the applications described herein, particularly when in vivo administration and treatment is contemplated. "Water-soluble" means soluble in aqueous fluids to about 1 mM or better. Such characteristics allow these texaphyrins to be useful in a biological environment. Improved water solubility can be achieved by, for example, substituents chosen from saccharides or hydroxylated substituents.

However, while the above-described texaphyrins are presently preferred compounds for use in the present invention, the invention is not limited thereto and any texaphyrin complex that exhibits activity both as a hydrolyzing agent for RNA polymers and as a photocleaving agent for RNA or DNA polymers may be useful in the practice of the invention.

The texaphyrin metal complexes of the present invention can be synthesized by procedures as described in the patents and applications previously incorporated herein by reference. For example, a nonaromatic texaphyrin of structure I is mixed together with a metal salt, a Br.o slashed.nsted base and an oxidant, in an organic solvent, and the mixture is allowed to react to form an aromatic texaphyrin metal complex. A preferred means is to stir the mixture at ambient temperature or to heat the mixture at reflux for at least two hours. ##STR2##

The nonaromatic texaphyrin I is conveniently produced by condensation of a tripyrrane aldehyde or ketone having structure A and a substituted orthophenylenediamine B: ##STR3##

One skilled in the art of organic synthesis in light of the present disclosure and the disclosures in the patents, applications and publications incorporated by reference herein could extend and refine the above basic synthetic chemistry to produce texaphyrins having various substituents. For example, polyether-linked polyhydroxylated groups, saccharide substitutions in which the saccharide is appended via an acetal-like glycosidic linkage, an oligosaccharide or a polysaccharide may be similarly linked to a texaphyrin. A doubly carboxylated texaphyrin in which the carboxyl groups are linked to the texaphyrin core via aryl ethers or functionalized alkyl substituents could be converted to various esterified products wherein the ester linkages serve to append further hydroxyl-containing substituents. Polyhydroxylated texaphyrin derivatives may be synthesized via the use of secondary amide linkages. Saccharide moieties may be appended via amide bonds. Polyhydroxylated texaphyrin derivatives containing branched polyhydroxyl (polyol) subunits may be appended to the texaphyrin core via aryl ethers or ester linkages.

Treatment of carboxylated texaphyrins with thionyl chloride p-nitrophenol acetate would generate activated acyl species suitable for attachment to monoclonal antibodies or other biomolecules of interest. Standard in situ coupling methods (e.g., 1,1'-carbonyldiimidazole) could be used to effect the conjugation.

The selectivity of the texaphyrins may be enhanced by covalently linking oligonucleotides onto the periphery of the macrocycle. Amides, ethers and thioethers are representative of linkages which may be used for this purpose. Oligonucleotides functionalized with amines at the 5'-end, the 3'-end, or internally at sugar or base residues may be modified post-synthetically with an activated carboxylic ester derivative of the texaphyrin complex. Alternatively, oligonucleotide analogs containing one or more thiophosphate or thiol groups may be selectively alkylated at the sulfur atom(s) with an alkyl halide derivative of the texaphyrin complex. The resultant oligonucleotide-complex conjugates may be designed so as to provide optimal catalytic interaction between a target nucleic acid and the bound texaphyrin. The oligonucleotide may be large enough to bind probably at least about 8 nucleotides of complementary nucleic acid. Specific methods for preparing texaphyrin-oligonucleotide conjugates are disclosed in WO 94/29316, previously incorporated herein by reference.

The use of texaphyrin complexes to hydrolyze RNA and also photocleave RNA or DNA in vivo as a treatment procedure relies on the effective localization of the complex to the site of desired cleavage. A site of desired cleavage may be a position novel to undesired organisms in terms of health care. A site of desired cleavage may be a DNA or an RNA encoding a product deleterious to the host or may be a normal DNA or RNA that is deleterious in some way. Treating native RNA or DNA with this new texaphyrin complex results in the texaphyrin complex binding to a complementary RNA or DNA sequence, respectively, via an appended oligonucleotide. The texaphyrin complex then cleaves the RNA or DNA proximal to this specific site. The binding of a conjugate to a DNA double helix will form a triple helix which has sufficient stability for effective cleavage to occur.

The texaphyrin complex-oligonucleotide conjugates of the present invention may be developed into antisense reagents. This antisense strategy provides a clear and rational method for new drug design because there is one requirement, namely that the antisense probe hybridize to its target molecule. The hybidization requirement is very well understood via complementary Watson-Crick or Hoogsteen base pairing. Unlike the present methods in the art which require screening of thousands of compounds and X-ray crystal structure analysis, the information needed for antisense technology is the sequence of the target. Treating native RNA or DNA with this texaphyrin complex-oligonucleotide conjugate results in the conjugate binding to a complementary RNA or DNA sequence, respectively, via the appended oligonucleotide. The texaphyrin complex then hydrolyzes and at the same time photocleaves the RNA, or hydrolyzes the RNA and photocleaves the DNA, as the case may be, proximal to this specific binding site. Attachment to the texaphyrin complex may cause the oligonucleotide antisense agent to take on some of the pharmacodynamic and biodistribution properties of the texaphyrin such as selective localization in tumors.

The texaphyrin-oligonucleotide conjugates may be useful for inhibiting the expression of a gene in an animal or in a particular tissue of an animal. They may also be useful in a method for targeted intracellular mRNA hydrolysis and photocleavage, or for targeted intracellular mRNA hydrolysis and DNA photocleavage.

The texaphyrin-oligonucleotide conjugates and present method of hydrolysis and photocleavage would have immediate applications for anti-viral and anti-bacterial therapy as well as cancers (an oligonucleotide complementary to an oncogene, for example) and inflammatory responses that are caused by the overexpression of certain proteins.

The following example is an illustration of the practice of the present invention, and is intended neither to define nor to limit the scope of the invention in any manner.

Example 1

The present example illustrates the site-specific, light-independent hydrolysis of RNA and the site-specific light-dependent photocleavage of DNA by yttrium(III) texaphyrin-DNA oligonucleotide conjugates. The RNA hydrolysis properties of the YTx conjugates are compared with those of analogous paramagnetic Dy(III)Tx conjugates, and the DNA photocleavage properties of the YTx conjugates are compared with those of analogous diamagnetic Lu(III)Tx conjugates.

The texaphyrin-oligonucleotide conjugate in each case had the following formula, where M is yttrium, dysprosium or lutetium: ##STR4##

Methods for the preparation of the above texaphyrins, as well as those of other texaphyrins and texaphyrin-oligonucleotide conjugates, are described in WO 94/29316, the disclosure of which is incorporated herein by reference. The texaphyrin-oligonucleotide conjugates used in this Example are set out in the drawing. The DNA sequences used in the conjugates were purchased from Keystone Labs, Menlo Park, Calif.; and the RNA sequences were purchased from Promega Corp., Madison, Wis.

RNA hydrolysis reactions were covered and incubated at 37° C. for 22 hr. DNA photocleavage reactions were irradiated for 15 min. at ambient temperature using a dye laser (Coherent, Palo Alto, Calif.) tuned to 732 nm using a power density of 150 mW/cm2.

At the end of the reaction time, the reaction samples containing radiolabeled DNA were precipitated with ethanol, then were dissolved in 10% aqueous piperidine solution (50 μL) and heated to 90° C. for 30 min. Water (500 μL) was added to the DNA samples, which were then dried on a Speedvac. The samples from the RNA hydrolysis reactions were precipitated with ethanol using standard methods. All samples were resuspended in 50% formamide loading buffer, denatured at 60° C. for 3 min., and analyzed by electrophoresis on a 20% denaturing polyacrylamide gel.

The autoradiograph indicated substantial cleavages only in those lanes which contained the appropriate complementary 20-mer YTx, DyTx, or LuTx conjugate. All cleavages occurred near the expected location of the YTx, DyTx, or LuTx complex upon hybridization of the conjugates with their targets. The cleavage locations on the 36-mers are indicated by arrows in the drawing. The YTx- and LuTx-mediated DNA cleavage bands co-migrated with bands generated by dimethylsulfate in the guanine-specific sequencing lanes. The cleavage patterns generated by the YTx and DyTx conjugates on RNA were similar. Cleavage patterns generated by the YTx and LuTx conjugates on DNA were essentially identical. The total efficiency of RNA hydrolysis by the YTx conjugates ranged from 25-35%. The total efficiency of DNA photocleavage by the YTx conjugates ranged from 50-60%.

These observations are consistent with a model whereby hybridization of the YTx conjugates to complementary sequences of DNA effects site-specific photomodification of guanine residues, and results in site-specific photocleavage upon workup under basic conditions. By contrast, in a dark reaction, the YTx conjugates effect site-specific hydrolysis of complementary RNA targets. Thus, the YTx-DNA conjugates were able to damage nucleic acids by two distinct mechanisms, hydrolysis and photocleavage. Further, as conjugates containing LuTx, a diamagnetic metallotexaphyrin analogous to YTx, have previously been shown to effect site-specific photocleavage of both DNA and RNA targets, the above data imply that YTx conjugates would also effect site-specific photocleavage of RNA targets.